Novartis Reports European Commission Approval Of Kymriah CAR-T Cell Therapy

Shutterstock photo

(RTTNews.com) - Novartis ( NVS ) announced the European Commission has approved Kymriah for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

Kymriah is a one-time treatment that uses a patient's own T cells to fight cancer, and the only chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in the EU for these two distinct B-cell malignancies.

Novartis expects to launch initially in the pediatric acute lymphoblastic leukemia indication, as the company continues to ramp up capacity.

Read the original article on RTTNews (http://www.rttnews.com/2929520/novartis-reports-european-commission-approval-of-kymriah-car-t-cell-therapy.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: World Markets , Stocks , Economy , Commodities
Referenced Symbols: NVS

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?